Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies

Martin, Antony; Downing, Jennifer; Cochrane, Madeleine; Collins, Brendan; Francis, Ben; Haycox, Alan; Alfirevic, Ana; Pirmohamed, Munir

doi:10.1016/j.critrevonc.2018.07.012

Cited by 6 publications

(3 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancers are usually classified into estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-positive (HER2+), or triple-negative breast cancer (TNBC) [3]. About 20% of breast cancers are an overexpression of HER2, a gene correlated with more aggression compared with other subtypes [4, 5]. Despite advances in the treatment of patients with this disease, it is often accompanied by poor prognosis of patients [6].…”

Section: Introductionmentioning

confidence: 99%

AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion

Zhang

Yin

et al. 2019

Disease Markers

View full text Add to dashboard Cite

Breast cancer (BC) is a type of malignant tumor originating from the epithelial tissue of the mammary gland, and about 20% of breast cancers are human epidermal growth factor receptor 2 positive (HER2+), which is a subtype with more aggression. Recently, HER2-positive breast cancer is often accompanied by poor prognosis of patients, and targeted therapy showed a promising prospect. To combat this disease, novel therapeutic targets are still needed. Adenylate kinase 4 (AK4) is a member of the adenylate kinase family and is expressed in the mitochondrial matrix. AK4 is involved in multiple cellular functions such as energy metabolism homeostasis. Interestingly, AK4 was observed highly expressed in several tumor tissues, and the involvement of AK4 in cancer development was generally revealed. However, the possible role of AK4 on the growth and development of breast cancer is still unclear. Here, we investigated the possible functions of AK4 on the progression of HER2-positive breast cancer. We found the high expression of AK4 in HER2-positive breast cancer tissues from patients who received surgical treatment. Additionally, AK4 expression levels were obviously correlated with clinical-pathological features, including pTNM stage (P = 0.017) and lymph node metastasis (P = 0.046). We mechanically confirmed that AK4 depletion showed the obvious impairment of cell proliferation and invasion in MCF7 and MDA-MB-231 cells. AK4 also facilitates tumor growth and metastasis of HER2-positive breast cancer in vivo. In conclusion, we identified and mechanically confirmed that AK4 is a novel therapeutic target of HER2-positive breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion

Zhang

Yin

et al. 2019

Disease Markers

View full text Add to dashboard Cite

show abstract

“…The socio-economic inequalities in testing and therapy utilization in breast cancer were less pronounced, despite the majority of research focusing on this cancer. This finding, along with a previous systematic review concluding equivocal associations between socioeconomic status and trastuzumab uptake [90], suggests that low socio-economic status may be less of a treatment barrier in breast cancer, at least as far as newer therapies are concerned. One possible explanation for this may be that breast cancer sub-type differentiation and the practice of hormone receptor status testing, and basing treatment on these results, are well established and routinely embedded in clinical practice (originating in the 1970s following the discovery of the estrogen receptor) [91].…”

Section: Discussionmentioning

confidence: 56%

Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis

Norris

Dew

Sharp

et al. 2020

BMC Med

View full text Add to dashboard Cite

Background Novel biological and precision therapies and their associated predictive biomarker tests offer opportunities for increased tumor response, reduced adverse effects, and improved survival. This systematic review determined if there are socio-economic inequalities in utilization of predictive biomarker tests and/or biological and precision cancer therapies. Methods MEDLINE, Embase, Scopus, CINAHL, Web of Science, PubMed, and PsycINFO were searched for peer-reviewed studies, published in English between January 1998 and December 2019. Observational studies reporting utilization data for predictive biomarker tests and/or cancer biological and precision therapies by a measure of socio-economic status (SES) were eligible. Data was extracted from eligible studies. A modified ISPOR checklist for retrospective database studies was used to assess study quality. Meta-analyses were undertaken using a random-effects model, with sub-group analyses by cancer site and drug class. Unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed for each study. Pooled utilization ORs for low versus high socio-economic groups were calculated for test and therapy receipt. Results Among 10,722 citations screened, 62 papers (58 studies; 8 test utilization studies, 37 therapy utilization studies, 3 studies on testing and therapy, 10 studies without denominator populations or which only reported mean socio-economic status) met the inclusion criteria. Studies reported on 7 cancers, 5 predictive biomarkers tests, and 11 biological and precision therapies. Thirty-eight studies (including 1,036,125 patients) were eligible for inclusion in meta-analyses. Low socio-economic status was associated with modestly lower predictive biomarker test utilization (OR 0.86, 95% CI 0.71–1.05; 10 studies) and significantly lower biological and precision therapy utilization (OR 0.83, 95% CI 0.75–0.91; 30 studies). Associations with therapy utilization were stronger in lung cancer (OR 0.71, 95% CI 0.51–1.00; 6 studies), than breast cancer (OR 0.93, 95% CI 0.78–1.10; 8 studies). The mean study quality score was 6.9/10. Conclusions These novel results indicate that there are socio-economic inequalities in predictive biomarker tests and biological and precision therapy utilization. This requires further investigation to prevent differences in outcomes due to inequalities in treatment with biological and precision therapies.

show abstract

“…See text for details. The percentage of TNBC [1], HER2-positive [5] and hormone receptor (HR)-positive [6] breast cancers are reported.…”

Section: Figurementioning

confidence: 99%

TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities

et al. 2018

View full text Add to dashboard Cite

Compared to other breast cancers, triple-negative breast cancer (TNBC) usually affects younger patients, is larger in size, of higher grade and is biologically more aggressive. To date, conventional cytotoxic chemotherapy remains the only available treatment for TNBC because it lacks expression of the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2), and no alternative targetable molecules have been identified so far. The high biological and clinical heterogeneity adds a further challenge to TNBC management and requires the identification of new biomarkers to improve detection by imaging, thus allowing the specific treatment of each individual TNBC subtype. The Systematic Evolution of Ligands by EXponential enrichment (SELEX) technique holds great promise to the search for novel targetable biomarkers, and aptamer-based molecular approaches have the potential to overcome obstacles of current imaging and therapy modalities. In this review, we highlight recent advances in oligonucleotide aptamers used as imaging and/or therapeutic agents in TNBC, discussing the potential options to discover, image and hit new actionable targets in TNBC.

show abstract

Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies

Cited by 6 publications

References 92 publications

AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion

AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion

Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis

TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities

Contact Info

Product

Resources

About